Introduction
Debate and controversy remain as to what is the best post-remission therapy for patients with AML. There is no dispute that some post-remission therapy is essential [1] [2] [3] [4] [5] [6] . There is also widespread agreement that sibling allogeneic bone marrow transplantation results in the best freedom from recurrence pattern [7] [8] [9] [10] . However, most patients do not have an HLA-matched donor, and the mortality of the treatment, particularly in those over 40, has been regarded as a major deterrent. Hence, HDT with ABMS has been investigated as an alternative [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Whilst engendering no 'graft-ver^Mi-leukaemia' effect, it has the advantage of not resulting in 'graftvemw-host-disease ' .
In 1988, a study began to evaluate the addition of HDT with ABMS to conventional consolidation therapy, in the hope of improving remission duration and survival.
Intermediate dose ara-C and TBI were chosen as the myeloablative regimen instead of cyclophosphamide and TBI, since it was felt that in the autologous setting, the best anti-leukaemic drug should be used. The results of this approach as used at three centres are reported below.
Patients and methods

Patients
Between July 1988 and May 1994, 144 consecutive patients under the age of 50 with newly-diagnosed AML were referred for treatment at the ICRF Department of Medical Oncology, St. Bartholomew's Hospital (SBH) and the Haematology Departments of the Ospedali Riuniti di Bergamo and Ospedale San Bortolo in Vicenza. Their clinical characteristics are shown in Table 1 .
The diagnosis was made according to the criteria of the French- American-British classification system [11] . Patients with acute promyelocytic leukaemia were excluded because of concern about the potential morbidity and mortality of such treatment, relative to the reasonably good prognosis of this subtype [22, 23] . No other patients were excluded; specifically, II patients with a preceding history of myelodysplasia which had progressed to AML were included. Fortythree other patients were found to have a degree of myelodysplasia concurrent with the diagnosis of AML. Fourteen of this group fulfilled the criteria for trilineage myelodysplasia (TMDS) as originally described by Brito-Babapulle et al. [24] , In the remainder, less marked dysplastic features were seen.
Cytogenetic data were available on 114 of 144 patients (79%). Details of cytogenetic abnormalities grouped in terms of prognostic category are shown in Table 2 .
Treatment
The study design is shown in Figure 1 . Remission induction therapy comprised Adriamycin. Cytosine arabinoside and 6-thioguanine [22] . If after two cycles of treatment there were still more than 30% blasts in a bone marrow aspirate, the treatment was deemed to have failed and the patient withdrawn from the study. In patients in whom CR was achieved, two further cycles of the same regimen were given as consolidation therapy, followed by HDT within three months of the last chemotherapy cycle.
Marrow was collected under general anaesthetic immediately prior to the HDT, (a bone marrow aspirate having been performed the day before collection to ensure continuing complete remission). The mononuclear cell fraction was isolated over Ficoll-Hypaque and cryopreserved in liquid nitrogen without any in vitro manipulation. The number of mononuclear cells considered to be sufficient to proceed to HDT was 2 x 10 7 /kg. Patients then received Cylosine arabinoside: 1 g/m 2 (given as a three-hour infusion), twice daily, for six days, followed by TBI: 200 cGy, twice daily for three days. On the following day, the thawed marrow was reinfused Seven patients who had an HLA-identical sibling donor electively had an allogeneic transplant in first remission.
Supportive care
Patients were cared for in single rooms, but for the last two years of the study were encouraged to leave the room and indeed to leave the building and go outside. Visitors, nursing and medical staff simply washed their hands before entering the room, staff touching the patient wore plastic aprons and disposable gloves. Prophylactic antibiotics (Framycetin, Nystatin and Colistin at SBH, Ciprofloxacin in Italy) were prescribed though not always taken. Prophylactic oral Fluconazole (for the duration of therapy) was used for the last three years of the study (see below). Acyclovir was given for one year at SBH, for three months in Italy.
Blood and platelets were transfused to maintain the haemoglobin at > 10 g/l and the platelets at >20 x 1O 9 /1. All blood products were irradiated (5000 cGy). Intravenous antibiotics were started empirically if clinically indicated and certainly when the temperature reached 38 °C. Intravenous Amphotericin B was used for suspected or proven fungal infection. Prednisolone eye drops were administered for the duration of HDT If, for any reason, a patient did not proceed to the planned HDT in first remission and developed recurrent leukaemia but second CR was achieved, myeloablative therapy with allogeneic or autologous BMT (or peripheral blood progenitor cell support) was used in second remission (seven patients).
Definitions
Overall survival is the time from diagnosis to death. Complete remission is defined as the point at which a normocellular bone marrow aspirate contained less than 5% blast cells with evidence of normal maturation of other marrow elements. Failure to achieve remission was classified as being due to either resistant leukaemia or treatmentrelated causes. Remission duration curves were censored at the time of allogeneic BMT for patients who had the latter treatment instead of ara-C + TBI + ABMS. 
Historical control group
One hundred thirty-three patients aged between fifteen and forty-nine who received adriamycin, cytosine arabinoside and 6-thioguanine as remission induction therapy followed by two cycles of identical consolidation therapy at the same three hospitals, prior to 1988 comprised a historical control group. Patients with AML-M3 were excluded. The clinical characteristics of the control group, together with those of the 106 patients eligible to receive ara-C + TBI + ABMS are shown in Table 3 .
Statistical methods
All patients achieving remission and hence considered eligible for HDTwere analysed together, in order to adhere to the 'intention to treat' principle. Survival curves were estimated by the Kaplan-Meier method [25] , and all analyses comparing overall and relapse-free survival in the treatment and control groups were assessed firstly by log-rank test and subsequently by stratified Cox proportional hazards regression [26] , with the centre being defined as the stratum.
In the first six months after diagnosis, there was a higher early mortality among control patients compared with the study group; in the subsequent six months, the 'study' group had a higher mortality rate. Over the total study period therefore, the hazard functions of the two groups were not proportional. Therefore, to assess any difference in overall survival between the study group and the historical controls, a 'piecewise hazard' was fitted to the data. As hazard ratios were roughly constant in the first and subsequent six months, the ratios of the hazard functions of the groups for these two periods were allowed to differ from those estimated elsewhere by use of a time-dependent Cox model. A similar strategy was carried out in modeling relapse-free survival. For the first six months, the difference between the two groups was small, but it became much greater subsequently. In order to allow for the non-proportionality of the hazard functions, a timedependent Cox regression model was used, with the hazard ratio for the treatment group in the first six months being allowed to differ from the hazard ratio thereafter.
For all comparisons between the study and control groups, the Figure 2 . Survival of all patients entered into the study.
treatment effect was assessed, having taken other prognostic factors into account. The latter comprised: age. gender, blast count, FAB subtype, history of myelodysplasia (MDS), tnlineage MDS concurrent with the diagnosis of AML, hepatomegaly, splenomegaly, or hepatosplenomegaly. Analyses of survival in the study group were performed by standard Cox regression. Cytogenetic sub-type was included as a prognostic factor in analyses within the study group but not in those comparing the study group with historical controls, because karyotyping was not routinely available at the time that the control patients were treated. The association between failure to respond to initial treatment and patient characteristics was assessed by maximum likelihood logistic regression for all terms apart from the FAB classification. As there were very few patients in some of the FAB categories, 'exact' logistic regression was required for this comparison. The association between early recurrence (17 patients) and the same patient characteristics was also assessed, in this case by 'exact' methods throughout, as there were relatively few early recurrences. All analyses were performed using the STATA statistical package [27] apart from exact logistic regression, for which the program LogXact was used [28] .
Results
Overall survival
Survival of all patients entered into the study is shown in Figure 2 ; 54 of 144 (38%) are alive, as of October 1999.
Outcome to initial therapy
Complete remission was achieved in 106 of 144 patients (73%), in 48 patients (45%) after one cycle of therapy. Thirty-three patients were deemed to have resistant leukaemia; thirty-one of the latter patients have died, two are alive having had alternative chemotherapy without HDT. There were five treatment-related deaths during remission induction, three from infection and two from other causes.
Prognostic factors for achievement ofCR
On univariate analysis, the only factor that correlated significantly with an increased likelihood of failure to enter CR was 'poor' cytogenetic sub-type (odds ratio for 'poor' vs. 'favourable' = 9.0; 95% confidence interval (95% CI): 1.32-61.1; P = 0.03, Table 4 ). The presence of 
High-dose treatment
One hundred six patients entered CR and were therefore eligible to receive HDT. In fact, only 61 did; 45 did not for the reasons shown in Table 5 , early recurrence being the most frequent cause (17 of 45 patients). Comparison of the clinical characteristics, incidence of antecedent MDS, concurrent TMDS and karyotype for these 17 patients and for the other 89 patients in whom CR was achieved, showed no significant differences (data not shown) by univariate analysis. Twelve patients were considered 'unfit to proceed'. This term encompasses a number of problems, including (in Italy), the presence of hepatitis infection and in some patients, very slow blood count recovery following remission induction or consolidation therapy. The presence of MDS (antecedent or concurrent) did not influence the likelihood of proceeding to HDT.
Toxicity of HDT
There were eight treatment-related deaths, seven from infection and one from haemorrhage. The first five deaths, from systemic fungal infection, occurred in the first two years of the study. After this, prophylactic oral fluconazole was given to all patients, with no deaths from fungal infection thereafter.
The median time to haemopoietic recovery was 25 days for neutrophils to reach 0. Figure 3 Recurrence-free survival and survival for 106 patients in whom CR was achieved.
• to haematological recovery. The median length of hospital stay following re-infusion of marrow, was 30 days with a range of 18 days to 2 months.
Overall survival and recurrence-free survival for the 106 patients eligible to receive HDT
Survival and recurrence-free survival by 'intention-totreat'are shown in Figure 3 . With a median follow-up of 5.5 years, 51 of 106 patients are alive without recurrence (48%), 55 have developed recurrent leukaemia between 1 month and 5.2 years. Survival according to cytogenetic subtype is shown in Figure 4 . If patients with a preceeding history of myelodysplasia are excluded from the analyses, there is no difference in outcome (data not shown).
Prognostic factors for survival and recurrence-free survival for the 106 patients in whom CR was achieved
On univariate analysis, only the presence of a 'poor' cytogenetic sub-type correlated adversely with survival (hazard ratio (HR) 3.12, 95% CI: 1.21-8.05, P = 0.02). On multivariate analysis (Table 6 ), this correlation was maintained, patients with a 'favourable' karyotype having a better prognosis than those with either a 'poor' karyotype or those classified within the category 'the rest', (P = 0.03 and 0.002, respectively). Male gender (P -0.03) and absence of hepatomegaly at presentation (P -0.03) also correlated with better survival (Table 6) . Recurrence-free survival according to cytogenetic Table 7 . Prognostic factors for relapse-free survival (patients eligible to receive ara-C + TBI + ABMS) by multivariate analysis.
sub-type is shown in Figure 5 . On univariate analysis, absence of hepatomegaly and splenomegaly correlated favourably (HR 2.23, 95% CI: 1.09-4.56, and 3.86, 95% CI: 1.40-11.1, P = 0.03 and 0.01, respectively). Cytogenetic subtype ('poor' worse than 'the rest') had an adverse correlation (HR 3.77, 95% CI: 1.45-9.77, P = 0.006). These correlations were confirmed on multivariate analysis (Table 7) .
Comparison with historical controls Survival
Overall survival for the 144 patients who commenced treatment is shown in Figure 6 in comparison with that of the historical 'control' group (n -197). There is a significant advantage in favour of the study population (log-rank, P < 0.001). Likewise, comparison by 'intention-to-treat' for the 106 patients planned to receive HDT, in comparison with the historical control group who entered CR and also received 2 cycles of consolidation therapy (n -133), shows a survival advantage in favour of HDT ( Figure 7 , log-rank, P = 0.009). On multivariate analysis, older age and the presence of hepatomegaly at presentation correlated adversely with survival, P -0.006 and 0.001, respectively (Table 8) . There was, however, only a trend towards survival benefit for the 106 patients eligible to receive HDT, compared with historical controls. The overall hazard ratio for survival (at one year and thereafter having adjusted for other prognostic factors) was 0.63 (95% CI: 0.37-1.05, P = 0.08). The benefit among patients receiving highdose treatment was greatest in the initial six months (hazard ratio for this period = 0.32, 95% CI: 0.08-1.31, P = 0.11) but was less marked in the ensuing six-month period (hazard ratio = 0.77, 95% CI: 0.41-1.43, P = 0.41).^= Figure 6 . Recurrence-free survival by 'intention-to-treat' analysis for 106 patients in whom CR was achieved vs. historical control group. Figure 8 shows recurrence-free survival for the HDT patients (by 'intention to treat') compared with that of the historical control group. Once more, there is a significant advantage in favour of the HDT, (log-rank, P -0.002). On multivariate analysis, little benefit was observed initially in patients receiving HDT (hazard ratio = 0.78, [95% CI: 0.41-1.46, P = 0.43 for the first six months), but thereafter, recurrence-free survival was significantly longer in patients eligible to receive HDT (hazard ratio = 0.50, 95% CI: 0.31-0.81, P = 0.005) ( Table 9 ). Apart from the favourable impact of HDT, the only other significant factor on multivariate analysis was hepatosplenomegaly at presentation which had an adverse effect, P = 0.002, (see Table 9 ). Table 9 Final model for recurrence-free survival (comparing 106 patients eligible for ara-C + TBI + ABMS with 133 control patients by multivariate analysis).
Recurrence-free survival
Hazard ratio (95% CI 
Outcome of 45 patients who did not receive ara-C + TBI + ABMS in first remission
Four of the seven patients who had an allograft in first CR remain well without recurrence; one died of transplant-related complications, two developed recurrent AML but are alive, having had further treatment. Only 4 of the remaining 38 patients remain in continuous complete remission without further therapy. Recurrence has occurred in 34 of 38, of whom it was only considered appropriate to re-treat 16 with curative intent. Second CR was achieved in 14 of 16 (thus 14 of 34 overall); nine of the latter 14 are alive without leukaemia, three having had an allogeneic transplant in second CR and 2 having received HDT with either autologous bone marrow (1) or peripheral blood progenitor cell support (1).
Outcome of patients who developed recurrent leukaemia following ara-C + TBI + ABMS in first remission
Nineteen of the sixty-one patients who received HDT in first remission have developed recurrent leukaemia between nine months and three and a half years. Only four were re-treated; second CR was achieved and followed by allograft in all. Two of the four are alive, two having died of toxicity related to the transplant procedure.
Discussion
These results show that a strategy of intending to complement conventional remission induction and consolidation therapy with ara-C + TBI + ABMS (or allograft if preferred) for patients with AML (excluding AML-M3) results in approximately half the patients in whom remission was achieved being alive at three years. This represents a significant improvement over historical control data from the three hospitals [22] . Whilst such historical comparisons can obviously be criticised, the control and study patients in this comparison received identical remission induction and consolidation chemotherapy. There were also no major differences in supportive care policies in use at the time. The addition of myeloablative therapy with ABMS therefore appears to have conferred benefit. These results are similar to survival data for allogeneic bone marrow transplantation [7] [8] [9] [10] in first remission of AML. Several recent randomised studies have addressed the question of post-remission therapy in AML [29] [30] [31] [32] [33] . The problem that has bedevilled them all is the 'attrition rate', whereby a large number of people commence treatment, but only about 40% are eventually allocated to the trial arm and can therefore provide information regarding the efficacy of treatment involving some sort of transplant procedure versus conventional chemotherapy. Interpretation of the results of such randomised studies is therefore complicated by the fact that patients who actually reach the point of receiving myeloablative therapy are, by definition, a highly selected group [29] [30] [31] [32] [33] [34] . As in the present study, early recurrence precludes a substantial proportion from receiving the planned treatment. Patients may be debilitated after completing conventional consolidation therapy so that consideration of HDT within the time-frame demanded by a protocol is unrealistic. Moreover, perceptions amongst patients and their doctors vary, from assuming that a treatment involving 'transplant' is somehow better, to fearing the potential morbidity and mortality associated with such therapy. There is also the philosophical dilemma that this treatment may be curing people a proportion of whom are cured already, as well as the statistical problem of 'event-free survival' being calculated from the time of the myeloablative therapy. The use of statistical analyses based on 'intention to treat' to some extent overcomes this.
The EORTC-GIMEMA study demonstrated superiority for myeloablative therapy with ABMS or allograft over chemotherapy alone in terms of disease-free survival. However, overall survival was not significantly different in the three treatment arms because some patients who developed recurrent leukaemia following conventional chemotherapy were able to receive myeloablative therapy + ABMS or an allograft in second remission, as in the present study [29] . Similarly, in the MRC AML 10 trial, the addition of HDT to four cycles of intensive chemotherapy significantly reduced the risk of recurrence [31] . However, in children and in patients with 'good-risk' disease, survival was equivalent for patients who received HDT in first CR and those who did not, because HDT could be given successfully in second remission. Some would therefore argue that HDT, in view of its potential mortality, morbidity, late effects and expense, should not be used in first remission in patients with a relatively favourable prognosis.
A French group (GOELAM) study in which patients who did not have an HLA identical sibling donor were randomised to receive intensive consolidation chemotherapy or HDT with ABMS showed no difference in disease-free survival or survival between the two groups [30] . The results for allogeneic BMT were similarly no better by 'intention to treat'analysis. However, all except the allogeneic transplant patients received a high-dose ara-C (3 g/m 2 ) containing cycle of treatment as consolidation, suggesting that the use of intensive (but nonmyeloablative) therapy such as high-dose ara-C is as effective as HDT. The results of the present study, show a significant difference in remission duration and a trend towards a difference in survival by 'intention to treat', in favour of ara-C + TBI + ABMS, when compared to those of patients receiving conventional therapy considered to be 'intensive' in the 1970s and 1980s. The Cancer and Leukaemia Group B (CALGB) study [5] and others in which intermediate or high-dose ara-C was used as consolidation therapy [1] [2] [3] [4] support the hypothesis that the difference between HDT and conventional chemotherapy has been diminished as the latter treatment has become more intensive, and therefore better.
In contrast with the original report from BritoBrabapulle et al. [24] , the finding of dysplastic features at the time of diagnosis did not correlate with poorer outcome. Thus, such patients should not be excluded from receiving HDT.
With conventional therapy, cytogenetic risk group is the most significant prognostic factor for remission duration and survival in AML [35] [36] [37] [38] [39] . This is also true for high-dose ara-C containing treatment [40] and for myeloablative therapy [41] [42] [43] [44] . These findings are confirmed by the results of the present study, although this statement has to be seen within the limitations posed by the fact that cytogenetic data were available on 79% (and not on all) of the patients. In addition, when the historical control group were treated, cytogenetic analysis was not routinely performed, therefore no comparison can be made within each cytogenetic risk group. It is therefore appropriate to exclude patients with a relatively good prognosis (i.e., those with t(8;21) or inversion 16) from studies of HDT in first remission. Such a 'risk adapted' strategy has been shown to be beneficial in childhood acute lymphoblastic leukaemia and reserves myeloablative therapy with its attendant morbidity and potential mortality for people who really need it. This approach has, in fact, now been adopted in the current MRC trial (AML 12).
The results of this study also confirm the need for improving the treatment overall for all patients with AML, irrespective of cytogenetic sub-type. The CR rate for patients in the study was relatively low; changing the remission induction therapy at the three hospitals to a regimen comprising Idarubicin, ara-C and etoposide has resulted in an improvement in CR rate (in similar patients) from 73% to 89% [45] . Other strategies are also currently being investigated; all trans retinoic acid has been showed to reduce levels of BCL-2 in myeloid blast cells [46, 47] and hence to increase their sensitivity to chemotherapy [48] . This approach warrants further investigation in the clinical setting.
HDT also needs to be safer if it is to be explored further. Peripheral blood progenitor cells offer a functionally equivalent source of haemopoietic progenitor cells capable of restoring long-term engraftment [49, 50] and have now virtually replaced autologous bone marrow in other haematological malignancies. The preliminary results for patients with AML at the three hospitals in which the study was conducted [45] and at other centres [51] [52] [53] [54] [55] [56] are encouraging with virtual halving of the times to neutrophil and platelet recovery. This should make the treatment safer and therefore more widely applicable.
